This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Dendreon's Aftermath

Spend time on Twitter with "bio run-up" traders, and you'll see even more esoteric catalysts being invented for quick trades -- stuff like New Drug Application (NDA) submissions, FDA acceptance of NDAs or announcements of Special Protocol Assessments.

What you don't see or hear are people interested in owning biotech stocks that are launching drugs. Heck, maybe there are valid reasons for not owning "commercial" biotech stocks, especially if valuations get too plump before actual sales (and profits?) are recorded. Does that sound a bit like Vertex Pharmaceuticals (VRTX - Get Report)?

What I do know for sure is that drug launches today are NOT a tradeable catalyst, and that's a very bad thing not to be. I miss the old days, but they seem long gone. Ignoring the new reality doesn't seem smart, unless you enjoy being pummeled over and over.


@pjkorman tweets (with some snark, which I appreciate), "Waiting for your take on SPPI report tomorrow. I know you're a fan."

Spectrum Pharmaceuticals (SPPI - Get Report) rates a "meh" for its second-quarter earnings report. The company was once again profitable, earning $7.2 million, or 12 cents a share, but gross margins, operating margins and net profit margins were all down sequentially due to higher expenses. Selling, general and administrative costs were up substantially, even accounting for non-cash charges in the quarter.

The performance of the colon cancer drug Fusilev is what we all focus on these days, and sales were down 2% sequentially to $33.9 million. Given Spectrum's big marketing push and continued shortages of the generic competitor leucovorin, I expected sequentially higher sales of Fusilev.

Spectrum said it was very happy with Fusilev sales in the quarter, noting that the company had supply issues of its own, which meant full demand for the drug could not be met. Spectrum signed on new Fusilev suppliers at the end of the June, so with continued leucovorin shortages, Spectrum better turn in a stronger performance in the third quarter.

If Fusilev sales once again fall or remain flat sequentially in the September quarter, it could mean that leucovorin resupply is eating into Fusilev sales, which is what Spectrum bears expect to happen. For the record, Spectrum said on its call that it expects equal or higher Fusilev sales in the third quarter.

2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
PATH $0.00 0.00%
AMAG $66.35 0.26%
DNDN $0.06 -6.02%
SPPI $6.34 0.48%
SGEN $43.23 -1.21%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs